BRCA1 and mesothelioma: Rucaparib demonstrated higher efficacy in a phase II trial, when given to patients with BAP1-negative or BRCA1-negative mesothelioma with a disease control rate of 58% at 12 weeks (95% CI 37–77; 15 of 26 patients), and at 24 weeks was 23% (9–44; six of 26 patients) [16].